

Giant Cell Arteritis

A study for patients with Giant Cell Arteritis (GCA)

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

Trial Status
Completed

Trial Runs In
14 Countries

Trial Identifier
NCT01791153 2011-006022-25
WA28119

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA. The study will consist of 2 parts: a 52-week double-blind treatment period (Part 1) followed by a 104-week open label long-term follow-up period (Part 2). In Part 1 of the study eligible participants will be randomized to receive either tocilizumab every week (qw) or every 2 weeks (q2w) or placebo for 52 weeks, with tapering oral daily doses of prednisone. After Week 52, participants in remission will stop study treatment and enter long-term follow-up, whereas participants with disease activity or flares will receive open-label tocilizumab or other treatment at the discretion of the investigator for a maximum period of 104 weeks.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT01791153 2011-006022-25 WA28119
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥50 Years

Healthy Volunteers
No